Skip to content

Clinical Efficacy Observation of Anoectochilus roxburghii in the Treatment of Mild Cognitive Impairment of the Type of "Xin Gan Huo Wang"

Clinical Efficacy Observation of Anoectochilus roxburghii in the Treatment of Mild Cognitive Impairment of the Type of "Xin Gan Huo Wang"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000919
Enrollment
Unknown
Registered
2025-05-07
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Interventions

Control Group:Placebo + Cognitive Training
Experimental Group:Anoectochilus roxburghii Concentrate + Cognitive Training

Sponsors

Fujian Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: a. Meet diagnostic criteria for mild cognitive impairment (MCI) and Syndrome of the Traditional Chinese Medicine type of Intense Fire in the Heart and Liver (Xin-Gan Huo Wang Zheng); b. Age = 60 years; c. No gender restrictions; d. Education level: At least primary school education with willingness to participate in the study and ability to cooperate in Montreal Cognitive Assessment (MoCA); e. Voluntary participation with signed informed consent form.

Exclusion criteria

Exclusion criteria: a. Moderate-to-severe cognitive impairment including: Clinically diagnosed dementia (multi-domain cognitive deficits + dependency in daily living activities) MoCA score significantly low (<18) or severe impairment in ADL (Activities of Daily Living) Sensory/language impairments preventing compliance with assessments b. Allergy to the decoction of fresh Anoectochilus roxburghii or its related components; c. Patients with constitution types such as: Yang deficiency Balanced constitution Phlegm-dampness Qi deficiency; d. Currently receiving other treatments that may significantly affect cognitive function such as: Anti-dementia drugs Antipsychotic medications e. Severe vision/hearing impairment aphasia or inability to complete cognitive scale assessments; f. History of drug/alcohol abuse or uncontrolled psychiatric disorders (e.g. depression); g.Currently participating in other clinical trials h.A history of allergies to placebo ingredients (xylitol caramel color) or an inability to accept the possibility of being assigned to the inactive drug group.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment (MoCA);

Secondary

MeasureTime frame
Untargeted Metabolomics;

Countries

China

Contacts

Public ContactWeidong He

Fujian Provincial People's Hospital

Hwd968@126.com15880086382

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026